Imagine a handheld device that works like a digital pregnancy test but for dangerous viruses. Instead of sending samples to a big lab and waiting days, it can spot threats in people, pets, or even mosquitoes right on the spot. It's like having a universal security scanner for germs that can be updated to find new threats quickly.
Current diagnostic systems are too slow and centralized, failing to detect emerging pandemic threats in remote areas or across different species (animals/insects) before they jump to humans.
Two portable diagnostic devices (including the industrial-grade Pixl) and six molecular assays for detecting Coronaviruses, Influenza, and Arboviruses.
If you are a device manufacturer dealing with slow lab turnaround times — this project developed 2 IVDR certified devices that provide rapid, point-of-care detection for viruses like SARS-CoV-2 and Influenza.
If you are a clinic dealing with cross-species virus outbreaks — this project developed molecular assays that work across humans and animals, allowing for a unified monitoring system in one place.
If you are an agency dealing with mosquito-borne disease tracking — this project developed a pocket-size device (Pixl) capable of detecting Zika, Dengue, and West Nile virus in mosquito extracts.
Based on available project data, specific pricing is not mentioned, but the project objective is to create cost-effective tools for resource-limited settings.
Yes, the project has already produced an industrial grade-manufactured pocket size device called Pixl.
Based on available project data, the project builds on the commercial success of the Pebble platform, but specific licensing terms for the new assays are not provided.
The project intends to deliver 2 IVDR certified devices, ensuring they meet European regulatory requirements for in vitro diagnostics.
The project runs from 2023-12-01 to 2027-05-31, with a goal to deliver the devices and 6 assays within a 36-month window.
The consortium is highly diversified with 11 partners across 8 countries, blending academic research (2 universities, 4 research centers) with industrial application (2 industry partners, 3 SMEs). The 18% industry ratio suggests a strong push toward commercialization, supported by a mix of European and African partners to ensure global applicability.
Contact IDRYMA TECHNOLOGIAS KAI EREVNAS in Greece
Contact us to explore licensing opportunities for the Pixl device and DAMP amplification assays.
